Inventor · disambiguated record
Jonathan Alexander Terrett
Also filed as: TERRETT JONATHAN · TERRETT JONATHAN A · TERRETT JONATHAN ALEXANDER
64 granted patents·82 pending applications·566 citations·filing 1997–2025
99Inventor score
Files withCRISPR THERAPEUTICS AG51CYTOMX THERAPEUTICS INC21OXFORD BIOTHERAPEUTICS LTD10TERRETT JONATHAN ALEXANDER9TERRETT JONATHAN A7
Top patents by PatentIndex Score
146 records- 0198US11191783B2Materials and methods for engineering cells and uses thereof in immuno-oncologyCRISPR THERAPEUTICS AG·Filed 2020·Granted Dec 7, 2021·6 cites·19 claims
- 0298US11166985B2Materials and methods for engineering cells and uses thereof in immuno-oncologyCRISPR THERAPEUTICS AG·Filed 2020·Granted Nov 9, 2021·10 cites·14 claims
- 0398US11135247B2Materials and methods for engineering cells and uses thereof in immuno-oncologyCRISPR THERAPEUTICS AG·Filed 2020·Granted Oct 5, 2021·6 cites·20 claims
- 0498US11071755B1Materials and methods for engineering cells and uses thereof in immuno-oncologyCRISPR THERAPEUTICS AG·Filed 2020·Granted Jul 27, 2021·7 cites·24 claims
- 0598US11013767B2Materials and methods for engineering cells and uses thereof in immuno-oncologyCRISPR THERAPEUTICS AG·Filed 2020·Granted May 25, 2021·5 cites·13 claims
- 0698US10736919B2Materials and methods for engineering cells and uses thereof in immuno-oncologyCRISPR THERAPEUTICS AG·Filed 2019·Granted Aug 11, 2020·13 cites·11 claims
- 0798US10179817B2Anti-CD71 antibodies, activatable anti-CD71 antibodies, and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2016·Granted Jan 15, 2019·36 cites·58 claims
- 0897US11207351B2Materials and methods for engineering cells and uses thereof in immuno-oncologyCRISPR THERAPEUTICS AG·Filed 2021·Granted Dec 28, 2021·3 cites·20 claims
- 0997US10881689B2Materials and methods for engineering cells and uses thereof in immuno-oncologyCRISPR THERAPEUTICS AG·Filed 2019·Granted Jan 5, 2021·7 cites·29 claims
- 1097US10857184B2Materials and methods for engineering cells and uses thereof in immuno-oncologyCRISPR THERAPEUTICS AG·Filed 2019·Granted Dec 8, 2020·9 cites·7 claims
- 1197US10745481B2Anti-CD166 antibodies, activatable anti-CD166 antibodies, and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2016·Granted Aug 18, 2020·22 cites·88 claims
- 1297US10729725B2Materials and methods for engineering cells and uses thereof in immuno-oncologyCRISPR THERAPEUTICS AG·Filed 2019·Granted Aug 4, 2020·7 cites·29 claims
- 1397US8268970B2Human antibodies that bind mesothelin, and uses thereofTERRETT JONATHAN A·Filed 2008·Granted Sep 18, 2012·65 cites·7 claims
- 1495US11753466B2Anti-CD166 antibodies, activatable anti-CD166 antibodies, and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2019·Granted Sep 12, 2023·7 cites·64 claims
- 1595US11298378B2Materials and methods for engineering cells and uses thereof in immuno-oncologyCRISPR THERAPEUTICS AG·Filed 2021·Granted Apr 12, 2022·2 cites·29 claims
- 1695US11202802B2Materials and methods for engineering cells and uses thereof in immuno-oncologyCRISPR THERAPEUTICS AG·Filed 2021·Granted Dec 21, 2021·2 cites·19 claims
- 1795US10669339B2Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2019·Granted Jun 2, 2020·10 cites·44 claims
- 1895US10233244B2Anti-ITGA3 antibodies, activatable anti-ITGA3 antibodies, and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2016·Granted Mar 19, 2019·26 cites·48 claims
- 1995US7261892B2Methods for diagnosis and treatment of epithelial-derived cancersCELLTECH R&D LTD·Filed 2004·Granted Aug 28, 2007·53 cites·3 claims
- 2094US11267896B2Anti-CD71 antibodies, activatable anti-CD71 antibodies, and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2018·Granted Mar 8, 2022·10 cites·34 claims
- 2194US11254912B2Methods and compositions for treating cancerCRISPR THERAPEUTICS AG·Filed 2021·Granted Feb 22, 2022·5 cites·14 claims
- 2294US10336824B2Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of thereofCYTOMX THERAPEUTICS INC·Filed 2016·Granted Jul 2, 2019·16 cites·48 claims
- 2394US9228023B2Anti-ROR1 antibodies and methods of use for treatment of cancerROHLFF CHRISTIAN·Filed 2011·Granted Jan 5, 2016·46 cites·102 claims
- 2494US8399623B2Human antibodies that bind mesothelin, and uses thereofTERRETT JONATHAN A·Filed 2012·Granted Mar 19, 2013·25 cites·7 claims
- 2594US8222375B2Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodiesTERRETT JONATHAN ALEXANDER·Filed 2006·Granted Jul 17, 2012·28 cites·9 claims
- 2693US11471491B1Materials and methods for engineering cells and uses thereof in immuno-oncologyCRISPR THERAPEUTICS AG·Filed 2021·Granted Oct 18, 2022·1 cites·18 claims
- 2793US9732160B2Methods of treating acute myeloid leukemia with antibodies to bone marrow stromal antigen 1OXFORD BIOTHERAPEUTICS LTD·Filed 2015·Granted Aug 15, 2017·8 cites·7 claims
- 2892US11649438B2Methods and compositions for treating cancerCRISPR THERAPEUTICS AG·Filed 2021·Granted May 16, 2023·2 cites·18 claims
- 2992US9102738B2Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7)TERRETT JONATHAN ALEXANDER·Filed 2012·Granted Aug 11, 2015·18 cites·7 claims
- 3091US11046759B2Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2016·Granted Jun 29, 2021·4 cites·58 claims
- 3191US8383779B2Human antibodies that bind mesothelin, and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2012·Granted Feb 26, 2013·12 cites·7 claims
- 3290US8680247B2Monoclonal antibodies against glypican-3TERRETT JONATHAN ALEXANDER·Filed 2008·Granted Mar 25, 2014·23 cites·21 claims
- 3389US11622977B2Materials and methods for engineering cells and uses thereof in immuno-oncologyCRISPR THERAPEUTICS AG·Filed 2018·Granted Apr 11, 2023·1 cites·25 claims
- 3489US9175092B2Antibodies to bone marrow stromal antigen 1OXFORD BIOTHERAPEUTICS LTD·Filed 2013·Granted Nov 3, 2015·5 cites·14 claims
- 3589US7745156B2Methods for diagnosis and treatment of epithelial-derived cancersUCB PHARMA SA·Filed 2007·Granted Jun 29, 2010·11 cites·17 claims
- 3688US11926676B2Masked chimeric antigen receptor specific to tyrosine-protein kinase like 7 (PTK7) and immune cells expressing suchCRISPR THERAPEUTICS AG·Filed 2021·Granted Mar 12, 2024·1 cites·30 claims
- 3788US8425904B2Human antibodies that bind mesothelin, and uses thereofTERRETT JONATHAN A·Filed 2012·Granted Apr 23, 2013·9 cites·17 claims
- 3888US2023302053A1Materials and methods for engineering cells and uses thereof in immuno-oncologyCRISPR THERAPEUTICS AG·Filed 2023·Application pending·0 cites
- 3986US12459999B2Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2022·Granted Nov 4, 2025·0 cites·8 claims
- 4084US11389481B2Allogeneic cell therapy of B cell malignancies using genetically engineered T cells targeting CD19CRISPR THERAPEUTICS AG·Filed 2021·Granted Jul 19, 2022·1 cites·20 claims
- 4184US10081682B2Conjugated antibodies against LY75 for the treatment of cancerOXFORD BIOTHERAPEUTICS LTD·Filed 2014·Granted Sep 25, 2018·8 cites·21 claims
- 4282US11174316B2Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2019·Granted Nov 16, 2021·1 cites·19 claims
- 4382US2025144183A1Methods and compositions for treating lipoprotein-related diseasesCRISPR THERAPEUTICS AG·Filed 2024·Application pending·0 cites
- 4482US2025011771A1Methods and compositions for treating lipoprotein-related diseasesCRISPR THERAPEUTICS AG·Filed 2024·Application pending·0 cites
- 4581US10239956B2Nucleic acid encoding bone marrow stromal antigen 1 antibodyOXFORD BIOTHERAPEUTICS LTD·Filed 2017·Granted Mar 26, 2019·1 cites·12 claims
- 4681US2025011743A1Methods and compositions for treating angiopoietin-like 3 (angptl3) related conditionsCRISPR THERAPEUTICS AG·Filed 2024·Application pending·0 cites
- 4781US2025043261A1Methods and compositions for treating angiopoietin-like 3 (angptl3) related conditionsCRISPR THERAPEUTICS AG·Filed 2024·Application pending·0 cites
- 4881US2025163174A1Conjugated antibodies against ly75 for the treatment of cancerOXFORD BIOTHERAPEUTICS LTD·Filed 2024·Application pending·0 cites
- 4980US12037616B2Methods and compositions for treating angiopoietin-like 3 (ANGPTL3) related conditionsCRISPR THERAPEUTICS AG·Filed 2023·Granted Jul 16, 2024·0 cites·20 claims
- 5080US9932411B2AntibodiesOXFORD BIOTHERAPEUTICS LTD·Filed 2014·Granted Apr 3, 2018·5 cites·24 claims
Showing the top 50 of 146 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Jonathan Alexander Terrett files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →